These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2639756)

  • 1. A new effector mechanism for antibodies: catalytic cleavage of peptide bonds.
    Paul S
    Cold Spring Harb Symp Quant Biol; 1989; 54 Pt 1():283-6. PubMed ID: 2639756
    [No Abstract]   [Full Text] [Related]  

  • 2. Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies.
    Paul S; Mei S; Mody B; Eklund SH; Beach CM; Massey RJ; Hamel F
    J Biol Chem; 1991 Aug; 266(24):16128-34. PubMed ID: 1874750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies.
    Nishiyama Y; Bhatia G; Bangale Y; Planque S; Mitsuda Y; Taguchi H; Karle S; Paul S
    J Biol Chem; 2004 Feb; 279(9):7877-83. PubMed ID: 14676184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic activity of anti-ground state antibodies, antibody subunits, and human autoantibodies.
    Paul S
    Appl Biochem Biotechnol; 1994; 47(2-3):241-53; discussion 253-5. PubMed ID: 7944341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide: its interactions with calmodulin and catalytic antibodies.
    Paul S; Ebadi M
    Neurochem Int; 1993 Sep; 23(3):197-214. PubMed ID: 8220166
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficient vasoactive intestinal polypeptide hydrolyzing autoantibody light chains selected by phage display.
    Tyutyulkova S; Gao QS; Thompson A; Rennard S; Paul S
    Biochim Biophys Acta; 1996 Aug; 1316(3):217-23. PubMed ID: 8781541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity chromatography of catalytic autoantibody to vasoactive intestinal peptide.
    Paul S; Volle DJ; Mei S
    J Immunol; 1990 Aug; 145(4):1196-9. PubMed ID: 2380555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease.
    Bangale Y; Karle S; Planque S; Zhou YX; Taguchi H; Nishiyama Y; Li L; Kalaga R; Paul S
    FASEB J; 2003 Apr; 17(6):628-35. PubMed ID: 12665475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalytic hydrolysis of VIP in pregnant women with asthma.
    Olopade CO; Yu J; Abubaker J; Mensah E; Paul S
    J Asthma; 2006 Aug; 43(6):429-32. PubMed ID: 16952860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody.
    Paul S; Volle DJ; Beach CM; Johnson DR; Powell MJ; Massey RJ
    Science; 1989 Jun; 244(4909):1158-62. PubMed ID: 2727702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of protease activity in antibody subunits.
    Sun M; Li L; Gao QS; Paul S
    Ann N Y Acad Sci; 1995 Sep; 764():573-5. PubMed ID: 7486588
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of oral mucous membrane pemphigoid with IgG antibodies to integrin α6β4.
    Miyamoto S; Chikazu D; Yasuda T; Enomoto A; Oh-i T; Hirako Y; Tsuchisaka A; Yasukochi A; Sogame R; Teye K; Koga H; Ishii N; Qian H; Li X; Hashimoto T
    Br J Dermatol; 2014 Dec; 171(6):1555-7. PubMed ID: 24836504
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoantibody catalysis: no longer hostage to Occam's razor.
    Paul S
    Ann N Y Acad Sci; 1998 Dec; 865():238-46. PubMed ID: 9928017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyanions inhibit binding of human autoantibodies to certain cellular proteins.
    Kabakov AE; Griaznova YB; Saenko VA; Poverenny AM
    Immunol Lett; 1990 Dec; 26(3):221-5. PubMed ID: 2086449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalytic autoantibodies to vasoactive intestinal peptide.
    Paul S; Gao QS; Huang H; Sun M; Thompson A; Rennard S; Landers D
    Chest; 1995 Mar; 107(3 Suppl):125S-126S. PubMed ID: 7874991
    [No Abstract]   [Full Text] [Related]  

  • 16. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs.
    Brezski RJ; Luongo JL; Petrone D; Ryan MH; Zhong D; Tam SH; Schmidt AP; Kruszynski M; Whitaker BP; Knight DM; Jordan RE
    J Immunol; 2008 Sep; 181(5):3183-92. PubMed ID: 18713989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-immunoglobulin serum proteins prevent the binding of IgG from normal rats and from rats with Th2-mediated autoimmune glomerulonephritis to various autoantigens including glomerular antigens.
    Druet E; Praddaude F; Druet P; Dietrich G
    Eur J Immunol; 1998 Jan; 28(1):183-92. PubMed ID: 9485198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate-driven formation of a proteolytic antibody light chain.
    Gao QS; Sun M; Tyutyulkova S; Webster D; Rees A; Tramontano A; Massey RJ; Paul S
    Ann N Y Acad Sci; 1995 Sep; 764():567-9. PubMed ID: 7486586
    [No Abstract]   [Full Text] [Related]  

  • 19. Specific binding of vasoactive intestinal peptide to human circulating mononuclear cells.
    Ottaway CA; Bernaerts C; Chan B; Greenberg GR
    Can J Physiol Pharmacol; 1983 Jul; 61(7):664-71. PubMed ID: 6311383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrolysis by catalytic IgGs of microRNA specific for patients with schizophrenia.
    Ermakov EA; Ivanova SA; Buneva VN; Nevinsky GA
    IUBMB Life; 2018 Feb; 70(2):153-164. PubMed ID: 29341394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.